Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/detail.php on line 234

Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 82

Warning: array_push() expects parameter 1 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 85
Pharmalicensing | Life Science's Global Technology Marketplace
Save this technology
close
Save to Existing Project
Save to a New Project
Cartexan® - Chondroitin Sulfate
Bioiberica Spain flag Spain
Abstract ID:
Chondroitin Sulfate...
Contact Monica Gomez Navarro
Participants
You
Email me a copy of this message
MECHANISM OF ACTION
Immediate delivery

Cartexan 400 mg Chondroitin Sulfate is indicated for the symptomatic treatment of osteoarthritis of the hip and knee.


Currently authorized and commercialized in Finland.


Available for outlicensing; under registration in several countries.

FEATURED
Last Updated Nov 2016
Technology Type THERAPEUTIC
Phase of Development REGISTERED / FINISHED PRODUCT
CORPORATION